Published in J Genet Couns on April 01, 2004
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. Genet Test (2007) 1.16
Standards of care in diagnosis and testing for hereditary colon cancer. Fam Cancer (2007) 1.09
Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw (2010) 1.05
Assessment of clinical practices among cancer genetic counselors. Fam Cancer (2010) 1.01
Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet (2012) 0.95
Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med (2011) 0.95
On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children. Fam Cancer (2009) 0.95
Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial. J Natl Cancer Inst (2014) 0.93
The role of numeracy on client knowledge in BRCA genetic counseling. Patient Educ Couns (2009) 0.91
Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol (2013) 0.91
In their own words: treating very young BRCA1/2 mutation-positive women with care and caution. PLoS One (2014) 0.90
Coherence and completeness of population-based family cancer reports. Cancer Epidemiol Biomarkers Prev (2010) 0.89
Testicular cancer and genetics knowledge among familial testicular cancer family members. J Genet Couns (2008) 0.87
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
Impact of genetic notification on smoking cessation: systematic review and pooled-analysis. PLoS One (2012) 0.85
Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women. Fam Cancer (2012) 0.84
Cancer risk assessment by rural and Appalachian family medicine physicians. J Rural Health (2009) 0.84
Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance. J Genet Couns (2015) 0.84
Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together. Patient Educ Couns (2009) 0.83
Working towards a risk prediction model for neural tube defects. Birth Defects Res A Clin Mol Teratol (2012) 0.83
Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice. Semin Nephrol (2010) 0.83
Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes. Fam Cancer (2013) 0.82
Estimating the referral rate for cancer genetic assessment from a systematic review of the evidence. Br J Cancer (2007) 0.82
Completeness of pedigree and family cancer history for ovarian cancer patients. J Gynecol Oncol (2014) 0.82
Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs. J Cancer Educ (2012) 0.81
Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations. Fam Cancer (2009) 0.81
Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories. JCO Precis Oncol (2017) 0.80
Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease. BMC Med Genet (2010) 0.78
Genetic risk, perceived risk, and cancer worry in daughters of breast cancer patients. J Genet Couns (2010) 0.78
Breast cancer in the young: role of the geneticist. J Thorac Dis (2013) 0.78
Hereditary cancer risk assessment: essential tools for a better approach. Hered Cancer Clin Pract (2013) 0.78
Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors. J Genet Couns (2015) 0.77
Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. Can Urol Assoc J (2014) 0.77
Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genet Mol Biol (2016) 0.76
Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. J Genet Couns (2016) 0.76
Prevalence and detection of psychosocial problems in cancer genetic counseling. Fam Cancer (2015) 0.75
Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up. J Clin Oncol (2016) 0.75
The Brazilian Hereditary Cancer Network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil. Genet Mol Biol (2016) 0.75
Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med (2016) 0.75
The Consequences of a BRCA Mutation in Women. J Adv Pract Oncol (2015) 0.75
Renal cell cancers: unveiling the hereditary ones and saving lives-a tailored diagnostic approach. Int Urol Nephrol (2017) 0.75
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA (2005) 4.93
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Recommendations for returning genomic incidental findings? We need to talk! Genet Med (2013) 3.23
Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA (2007) 2.91
Application of breast cancer risk prediction models in clinical practice. J Clin Oncol (2003) 2.19
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Rethinking the patient: using Burden of Treatment Theory to understand the changing dynamics of illness. BMC Health Serv Res (2014) 1.81
Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology (2005) 1.70
Imaging of the ovary. Technol Cancer Res Treat (2004) 1.55
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 1.34
A HOXA13 allele with a missense mutation in the homeobox and a dinucleotide deletion in the promoter underlies Guttmacher syndrome. Hum Mutat (2002) 1.31
Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis. Obstet Gynecol (2014) 1.31
What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test (2002) 1.25
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov (2012) 1.25
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res (2008) 1.24
Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns (2006) 1.19
Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test (2005) 1.12
Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat (2011) 1.07
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol (2002) 1.06
Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: a case report and literature review. Hum Pathol (2011) 1.06
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient Educ Couns (2011) 1.03
Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Hum Mol Genet (2010) 1.00
Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk. Am J Med Genet A (2003) 0.99
Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference? J Genet Couns (2012) 0.97
Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Intern Med (2005) 0.97
Genetic information: Special or not? Responses from focus groups with members of a health maintenance organization. Am J Med Genet A (2007) 0.96
Personalized cancer genetics training for personalized medicine: improving community-based healthcare through a genetically literate workforce. Genet Med (2011) 0.95
Breast cancer screening behaviors among African American women with a strong family history of breast cancer. Prev Med (2006) 0.93
Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Womens Health (2009) 0.91
The relationship of nondirectiveness to genetic counseling: report of a workshop at the 2003 NSGC Annual Education Conference. J Genet Couns (2006) 0.91
Nutritional supplements and other complementary medicines for infantile colic: a systematic review. Pediatrics (2011) 0.91
Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior? Findings from a population-based study. Public Health Genomics (2009) 0.88
Retention of African American women in cancer genetics research. Am J Med Genet A (2008) 0.88
A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep (2007) 0.88
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer (2010) 0.88
Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns (2005) 0.88
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer (2007) 0.86
Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers. Cancer (2009) 0.85
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions. Mol Diagn Ther (2013) 0.85
Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the National Society of Genetic Counselors. J Genet Couns (2005) 0.83
Adjusting to pancreatic cancer: perspectives from first-degree relatives. Palliat Support Care (2009) 0.82
Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs. J Cancer Educ (2012) 0.81
Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer. Obstet Gynecol (2007) 0.81
Effects of counseling Ashkenazi Jewish women about breast cancer risk. Cultur Divers Ethnic Minor Psychol (2006) 0.81
Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. Fam Cancer (2009) 0.80
Reliable measurement of glycated hemoglobin in frozen blood samples: implications for epidemiologic studies. Clin Chem (2002) 0.80
BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer. Community Genet (2008) 0.80
Familial multiple pilomatrixomas as a presentation of attenuated adenomatosis polyposis coli. J Cutan Pathol (2011) 0.79
The needs of mothers with severe mental illness: a comparison of assessments of needs by staff and patients. Arch Womens Ment Health (2008) 0.79
Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev (2015) 0.78
Pyruvate supplementation for weight loss: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Food Sci Nutr (2014) 0.78
National Society of Genetic Counselors code of ethics. J Genet Couns (1992) 0.78
Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology (2014) 0.77
Dietary iron intake and serum ferritin concentration in 213 patients homozygous for the HFEC282Y hemochromatosis mutation. Can J Gastroenterol (2012) 0.76
Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. J Med Internet Res (2016) 0.76
Planning the genome institute's future. Science (2003) 0.75
Letter to the editor by megan Hall. Curr Genomics (2013) 0.75
Implications of human genome research: impact on graduate education in genetic counseling. J Genet Couns (1993) 0.75
"What would you do if you were me?" Effects of counselor self-disclosure versus non-disclosure in a hypothetical genetic counseling session. J Genet Couns (2010) 0.75
Comparison of the incidence of pancreatic abnormalities between high risk and control patients: prospective pilot study with 3 Tesla MR imaging. J Magn Reson Imaging (2011) 0.75
National Society of Genetic Counselors Code of Ethics. J Genet Couns (2017) 0.75